好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Comparison of the Efficacy and Tolerability of Interferon Beta (IFN[beta]) Products Used as Initial or Follow-Up Therapy for the Treatment of Relapsing Multiple Sclerosis: Results from the QUASIMS Study
122
Authors/Disclosures
Duarte G. Machado, MD, FAAN (Hartford Healthcare Neurology) Dr. Machado has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Adamas. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ipsen. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merz. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva.
Michael A. De Georgia, MD (University Hospitals Cleveland Medical Center) Dr. De Georgia has nothing to disclose.